8-K: Relay Therapeutics Upsizes Stock Offering, Reports Q2 Results

Relay Therapeutics announced an amendment to its common stock sales agreement, increasing the at-the-market offering program to $462.98 million and reported its second quarter 2026 financial results, including a net loss of $83.7 million.

Summary

• Relay Therapeutics amended its common stock sales agreement with TD Securities (USA) LLC to increase the at-the-market offering program from $250 million to $462,978,049.
• As of August 6, 2026, the company had sold approximately $162,978,049 of its common stock under the existing agreement.
• The amendment allows for the sale of up to an additional $212,978,049 of common stock.
• The company reported financial results for the second quarter ended June 30, 2026, with revenue of $0.4 million, a decrease from $0.7 million in Q2 2025.
• Research and development expenses increased to $76.5 million in Q2 2026 from $63.9 million in Q2 2025.
• General and administrative expenses rose to $14.7 million in Q2 2026 from $13.6 million in Q2 2025.
• The net loss for Q2 2026 was $83.7 million, or $0.41 per share, compared to a net loss of $70.4 million, or $0.41 per share, in Q2 2025.
• As of June 30, 2026, the company had approximately $910.9 million in cash, cash equivalents, and investments, with an expected runway into 2029.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development, primarily due to the significant increase in the at-the-market offering size and the company's strong cash position, which supports ongoing clinical development. However, the increased net loss and decreased revenue warrant careful monitoring.

Positives

• The at-the-market offering program was significantly increased to $462,978,049, providing potential for substantial capital infusion.
• The company has a strong cash position of approximately $910.9 million as of June 30, 2026, with an expected runway into 2029.
• Initial positive clinical data for zovegalisib in vascular anomalies was presented, with 60% of patients achieving volumetric response and nearly all experiencing symptomatic improvement.
• The company is advancing its Phase 3 ReDiscover-2 trial in second-line breast cancer and plans to initiate a Phase 3 trial in first-line breast cancer in early 2027.
• A clinical supply agreement with Pfizer for atirmociclib for the planned first-line breast cancer study was secured.

Negatives

• Revenue decreased to $0.4 million in Q2 2026 from $0.7 million in Q2 2025.
• Net loss increased to $83.7 million in Q2 2026 from $70.4 million in Q2 2025.
• Research and development expenses increased by $12.6 million year-over-year.
• General and administrative expenses increased by $1.1 million year-over-year.

Risks

• The preliminary or interim results of clinical trials may not be predictive of future or final results.
• Relay Therapeutics' ability to successfully demonstrate the safety and efficacy of its drug candidates is subject to inherent risks.
• The timing and outcome of interactions with regulatory authorities are uncertain.
• Obtaining, maintaining, and protecting intellectual property presents ongoing challenges.
• Global economic uncertainty, geopolitical instability, and public health epidemics could impact clinical trials and operations.
• Significant political, trade, or regulatory developments beyond the company's control could arise.

Future Outlook

The company expects its current cash, cash equivalents, and investments to be sufficient to fund its operating expenses and capital expenditure requirements into 2029. Key milestones include enrollment updates for the Phase 3 ReDiscover-2 trial by year-end 2026, regulatory updates for the planned Phase 3 1L breast cancer trial by year-end 2026, and data/regulatory updates for vascular anomalies by year-end 2026. A data update for the Phase 1/2 triplet combination is anticipated in the first half of 2027.

Management Comments

• "The second quarter marked continued momentum across our zovegalisib program, with advances in our frontline breast cancer development strategy and the presentation of initial clinical data at ISSVA 2026 for zovegalisib in patients with vascular anomalies," said Sanjiv Patel, M.D., President and Chief Executive Officer of Relay Therapeutics.
• "This progress, including the ongoing Phase 3 trial in second-line breast cancer and the triplet combination work to support development in frontline breast cancer, reinforces the promise of mutant-selective PI3K inhibition and strengthens our confidence in zovegalisib's potential across multiple patient populations."
• "Supported by a strong cash position with expected runway into 2029, we continue to focus on the execution of several clinical and regulatory milestones expected for zovegalisib this year as we work to develop potentially life-changing therapies for patients living with cancer and genetic disease."

Industry Context

StockSavvy.ai notes that Relay Therapeutics' announcement aligns with the broader trend in precision medicine, focusing on targeted therapies for specific genetic mutations. The increased ATM offering suggests a need for capital to fund extensive clinical development, particularly for zovegalisib, which is being explored in multiple indications. The collaboration with Pfizer for clinical supply also highlights the strategic partnerships common in the biopharmaceutical industry.

Comparison to Industry Standards

• The company's net loss of $83.7 million in Q2 2026 is consistent with many clinical-stage biopharmaceutical companies that are heavily investing in R&D without significant revenue generation.
• The cash position of over $900 million is substantial and provides a competitive advantage, allowing for extended runway compared to smaller, less capitalized peers.
• The development of mutant-selective PI3K inhibitors like zovegalisib is a key area of focus in oncology research, with several companies pursuing similar targets, though Relay's allosteric approach may offer differentiation.
• The objective response rate of 44% in heavily pre-treated patients for the zovegalisib triplet, while promising, needs to be compared against benchmarks for similar patient populations and treatment lines in advanced breast cancer.

Stakeholder Impact

• Shareholders: The increased ATM offering provides potential for additional capital, which could fund future growth and development, but also dilutes existing shareholders if shares are issued.
• Employees: Continued investment in R&D and clinical trials may lead to job security and growth opportunities, but increased net losses could raise concerns about long-term financial health.
• Creditors: The strong cash position and increased capital raise potential provide comfort regarding the company's ability to meet its financial obligations.

Next Steps

• File a Prospectus Supplement within two business days of August 6, 2026.
• Continue execution of the Phase 3 ReDiscover-2 trial in 2L breast cancer.
• Initiate Phase 3 1L breast cancer trial in early 2027, subject to regulatory feedback.
• Continue dose escalation for pediatric patients in the Phase 1/2 ReInspire trial.
• Present enrollment updates for Phase 3 ReDiscover-2 trial by year-end 2026.
• Provide regulatory updates for the planned Phase 3 1L breast cancer trial by year-end 2026.
• Provide data and regulatory updates for vascular anomalies by year-end 2026.
• Provide data update for Phase 1/2 triplet combination in 1H 2027.

Key Dates

Recommendation

The company is making progress in its clinical development programs, particularly with zovegalisib, and has a strong cash position. However, the increased net loss, decreased revenue, and the dilutive nature of the expanded ATM offering suggest a cautious approach. While the potential for future success is present, the current financial performance and ongoing R&D investment warrant a 'hold' recommendation until further clinical and financial milestones are achieved.

Keywords

at-the-market offering, common stock, capital raise, zovegalisib, breast cancer, vascular anomalies, clinical trials, financial results